Tocit XR Tablet 11 mg contains Tofacitinib 11 mg in an extended-release (XR) formulation, designed for the treatment of autoimmune conditions such as ulcerative colitis in adults. Tofacitinib is a Janus kinase (JAK) inhibitor that helps regulate the overactive immune system, reducing inflammation, preventing tissue damage, and controlling disease progression.
The extended-release formulation of Tocit XR allows for once-daily dosing, providing convenient and consistent therapeutic effects throughout the day. This tablet is particularly useful for patients with moderate to severe ulcerative colitis who require long-term management to maintain remission and prevent flare-ups.
রেজিস্টার্ড চিকিৎসকের পরামর্শ অনুযায়ী ঔষধ সেবন করুন
Tofacitinib 11 mg (Extended-Release)
Tocit XR works by selectively inhibiting Janus kinase (JAK) enzymes, which play a central role in the signaling of pro-inflammatory cytokines:
Immune system modulation – Reduces abnormal immune activity that causes chronic inflammation in the intestinal tract.
Anti-inflammatory effect – Decreases the production of inflammatory mediators, alleviating pain, diarrhea, and rectal bleeding associated with ulcerative colitis.
Tissue protection – Slows progression of mucosal damage in the colon, supporting long-term gut health and preventing complications.
The extended-release design maintains steady drug levels in the bloodstream, minimizing fluctuations and enhancing adherence to therapy.
Tocit XR Tablet 11 mg is indicated for:
Induction and maintenance of remission in moderate to severe ulcerative colitis in adult patients
Patients who have had an inadequate response, lost response, or were intolerant to conventional therapy, including corticosteroids or immunomodulators
Part of a comprehensive treatment plan for autoimmune intestinal inflammation under the supervision of a gastroenterologist
Recommended dose: 11 mg orally, once daily
Swallow the tablet whole; do not crush, chew, or split the XR tablet
Can be taken with or without food
Regular monitoring is essential, including blood counts, liver function, and kidney function
Avoid sudden discontinuation to prevent flare-ups of ulcerative colitis
Dose adjustments may be required in patients with moderate to severe liver or kidney impairment
Provides effective induction and maintenance of remission in ulcerative colitis
Reduces symptoms such as diarrhea, abdominal pain, rectal bleeding, and urgency
Convenient once-daily dosing improves adherence and patient convenience
Helps prevent long-term intestinal damage and complications
Offers a safe and effective alternative for patients intolerant or unresponsive to conventional therapies
Avoid use in patients with active infections, severe liver disease, or history of blood disorders
Monitor closely for infections, including tuberculosis, viral, bacterial, and fungal infections
Avoid live vaccines during treatment
Patients with history of cardiovascular disease, malignancy, or blood clotting disorders should be monitored carefully
Not recommended during pregnancy or breastfeeding unless specifically advised by a healthcare provider
Common side effects may include:
Upper respiratory tract infections
Headache
Nausea or diarrhea
Elevated cholesterol or liver enzyme levels
Mild fatigue
Serious side effects requiring immediate attention:
Severe infections or fever
Blood clots, such as deep vein thrombosis or pulmonary embolism
Unexplained bruising or bleeding
Shortness of breath or chest pain
Store below 30°C in a cool, dry place
Protect from moisture and direct sunlight
Keep the bottle tightly closed
Keep out of reach of children
Tocit XR Tablet 11 mg is an effective extended-release therapy for adults with moderate to severe ulcerative colitis, providing consistent symptom control and supporting long-term gut health under proper medical supervision.
Login Or Registerto submit your questions to seller
No none asked to seller yet